Hyaluronan synthase 2 (primary enzyme); Fibroblast hyaluronic acid synthesis pathway is not a canonical target name. (HAS2)

The fibroblast hyaluronic acid synthesis pathway refers to the process by which fibroblasts produce hyaluronic acid (HA), an important glycosaminoglycan of the extracellular matrix. This synthesis is catalyzed chiefly by the enzyme hyaluronan synthase 2 (HAS2) at the plasma membrane, using substrates UDP-glucuronic acid and UDP-N-acetylglucosamine. HA plays major roles in tissue hydration, elasticity, cellular migration, and wound healing. Alterations in fibroblast-driven HA production are implicated in numerous pathologies, including fibrosis, cardiovascular disease (ventricular remodeling after myocardial injury), cancer progression, inflammation, and degenerative conditions such as osteoarthritis. Drugs such as 4-methylumbelliferone can inhibit HAS activity and thereby reduce HA production, which is of potential therapeutic value in conditions like Graves' orbitopathy and cancer. Excessive HA production may, however, impair normal tissue repair or immune responses, constituting a therapeutic challenge.

Other names

Hyaluronan synthase 2HA synthase 2HAS2HA biosynthesis pathwayHyaluronic acid pathway

Inhibition of HA synthesis (e.g., 4-MU blocks the production of hyaluronan by inhibiting hyaluronan synthase enzymes); Supplementation with exogenous HA (used therapeutically to modify extracellular matrix in osteoarthritis and other pathologies).